Life Sciences MVP: Sullivan & Cromwell's Frank Aquila
This past year, Sullivan & Cromwell LLP's Frank Aquila guided Amgen Inc. in its $10.4 billion acquisition of Onyx Pharmaceuticals Inc., strengthening the biotechnology firm's cancer drug portfolio and earning him...To view the full article, register now.
Already a subscriber? Click here to view full article